Comparison of Ciprofol-Based and Propofol-Based Total Intravenous Anesthesia on Microvascular Decompression of Facial Nerve with Neurophysiological Monitoring: A Randomized Non-Inferiority Trial
Tao Zhu,Fang Kang,Ming-Ming Han,Fang He,Sen Jiang,Li-Na Hao,Xiang Huang,Juan Li
DOI: https://doi.org/10.2147/dddt.s459618
IF: 4.3188
2024-06-22
Drug Design Development and Therapy
Abstract:Tao Zhu, 1 Fang Kang, 1 Ming-Ming Han, 1 Fang He, 2 Sen Jiang, 2 Li-Na Hao, 1 Xiang Huang, 1 Juan Li 1 1 Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China; 2 Department of Electrophysiology, the First Affiliated Hospital of USTC, Division of life sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China Correspondence: Juan Li, Department of anesthesiology, the First Affiliated Hospital of USTC, Division of life sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China, Email Purpose: Ciprofol is a recently developed short-acting gamma-aminobutyric acid receptor agonist with a higher potency than that of propofol. As a new sedative drug, there are few clinical studies on ciprofol. We sought to examine the safety and efficacy of ciprofol use for general anesthesia in neurosurgical individuals undergoing neurosurgical surgery with intraoperative neurophysiological monitoring (IONM). Patients and Methods: This single-center, non-inferiority, single-blind, randomized controlled trial was conducted from September 13, 2022 to September 22, 2023. 120 patients undergoing elective microvascular decompression surgery (MVD) with IONM were randomly assigned to receive either ciprofol or propofol. The primary outcome of this study was the amplitude of intraoperative compound muscle action potential decline, and the secondary outcome included the indexes related to neurophysiological monitoring and anesthesia outcomes. Results: The mean values of the primary outcome in the ciprofol group and the propofol group were 64.7± 44.1 and 53.4± 35.4, respectively. Furthermore, the 95% confidence interval of the difference was − 25.78 to 3.12, with the upper limit of the difference being lower than the non-inferiority boundary of 6.6. Ciprofol could achieve non-inferior effectiveness in comparison with propofol in IONM of MVD. The result during anesthesia induction showed that the magnitude of the blood pressure drop and the incidence of injection pain in the ciprofol group were significantly lower than those in the propofol group (P< 0.05). The sedative drug and norepinephrine consumption in the ciprofol group was significantly lower than that in the propofol group (P< 0.05). Conclusion: Ciprofol is not inferior to propofol in the effectiveness and safety of IONM and the surgical outcome. Concurrently, ciprofol is more conducive to reducing injection pain and improving hemodynamic stability, which may be more suitable for IONM-related surgery, and has a broad application prospect. Keywords: anesthetics, abnormal muscle response, ciprofol, microvascular decompression Intraoperative neurophysiological monitoring (IONM) has become a routine monitoring method in functional neurosurgery. Microvascular decompression (MVD) of the facial nerve under neurophysiological monitoring is the first choice for possible radical treatment of hemifacial spasm. Clinical studies have confirmed that the application of IONM in MVD of the facial nerve was beneficial in improving surgical efficacy and reducing the probability of facial and auditory nerve injury. 1,2 Intravenous anesthesia is often used in surgery requiring IONM. Propofol is one of the most commonly used intravenous anesthetic sedative drugs in clinical practice, but has a great impact on respiration and circulation. Studies have shown that propofol can reduce blood pressure by 15–40% in patients, especially in the elderly. 3–5 Due to the limited anatomical structure of the MVD surgical approach, it takes a long time to separate the nerve and blood vessels. At the same time, most patients are middle-aged and elderly and are prone to hypotension. Perioperative blood pressure fluctuates frequently, and repeated use of vasoactive drugs is not conducive to the recovery of patients. 6 Meanwhile, the inhibitory effect on respiration and pain of the injection site caused by propofol causes great trouble to anesthesiologists. 7–9 There is a need to acquire an alternative drug for clinical anesthesiologists to choose from so that safety and comfort can be advanced without sacrificing efficacy. Ciprofol (HSK3486, produced by the Haisco Pharmaceutical Group Co. Ltd, Liao Ning, China), is a short-acting gamma-aminobutyric acid (GABA) receptor agonist developed in recent years, which has anesthetic and sedative effects. The special cyclopropyl and chiral structures enhance the stereoscopic effect of ciprofol, which has high -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal